|
Post by mango on Sept 24, 2018 16:50:28 GMT -5
That's even better. I'm sure they are already putting that money to good use. Al Mann once said that the NIH wanted to have an Al Mann Institute program after someone from there heard him talking about his idea of establishing a dozen or so institutes, dubbed as an “industrial development organization”.
|
|
|
Post by thekindaguyiyam on Sept 24, 2018 17:06:14 GMT -5
As far as I can see, the navigation to the “inhaled-powder-vaccines” page isn’t available by navigating the Technovax website. Can you confirm you can find it from the home page on their site? technovax.com/inhaled-powder-vaccines/
|
|
|
Post by patten1962 on Sept 24, 2018 18:21:15 GMT -5
I just got home can you tell me what prompted this post?
I am sure I missed something?
Very cool information. Wondering why today?
|
|
|
Post by MnkdWASmyRtrmntPlan on Sept 24, 2018 19:30:39 GMT -5
I just got home can you tell me what prompted this post? I am sure I missed something? Very cool information. Wondering why today? I assume it was this NIH grant dated Sept 12, 2018: TechnoVax Awarded $1.5 Million NIH Grant to Further Develop a Universal VLP-Based Influenza Vaccine September 12, 2018 10:10 AM Eastern Daylight Time
|
|
|
Post by patten1962 on Sept 24, 2018 20:24:54 GMT -5
I just got home can you tell me what prompted this post? I am sure I missed something? Very cool information. Wondering why today? I assume it was this NIH grant dated Sept 12, 2018: TechnoVax Awarded $1.5 Million NIH Grant to Further Develop a Universal VLP-Based Influenza Vaccine September 12, 2018 10:10 AM Eastern Daylight Time Thank you
|
|
|
Post by mango on Sept 24, 2018 21:37:29 GMT -5
Very interesting that Mike would specifically have vaccines included in today’s slides (which is not common practice by MannKind). The timing of this NIH SBIR grant award to TechnoVax is particularly interesting as well. It was on the same date that a notification of acknowledgement (an evidence of receipt) was made pertaining to payments made towards patent application fees—more specifically, a corrected international joint MannKind/TechnoVax patent application pertaining to vaccines. This MannKind/TechnoVax joint patent was published back in 2015, however, in November of 2017 a patent office examiner notified K&L Gates (International law firm representing) of certain patent claims that were under investigation for rejection. K&L Gates submitted response to the examiner with undue haste—and on June 12, 2018 MannKind received a Notice of Allowance. MannKind subsequently submitted Amendments and Drawings to be filed in the corrected patent application. On September 12, 2018, the same date that TechnoVax received an NIH SBIR grant for R&D of an universal VLP flu vaccine, an evidence of receipt for payment of patent application fees by K&L Gates was made. INHALABLE VACCINE COMPOSITIONS AND METHODSType: Application Filed: 25.10.2013 Publication Date: 08.10.2015 Applicants MANNKIND CORPORATION, TECHNOVAX, INC. Inventors: Chad C. Smutney (Watertown, CT), Andrea Leone-Bay (Ridgefield, CT), Jose M. Galarza (Scarsdale, NY), Hector Munoz (Scarsdale, NY), George R. Martin (Rockville, MD), Marshall L. Grant (Newtown, CT) Abstract (EN) Dry powder inhalable compositions and methods for using and making the compositions are disclosed for vaccinating a subject against disease. In particular, the compositions are inhalable dry powders useful for preventing and/or treating diseases caused by microorganisms, for example, microorganisms such as viral or bacterial pathogens, including, the influenza virus. In particular, the method comprises the administration of an inhalable composition comprising virus-like particles and/or specific protein/s or antigenic peptides, peptide fragments and/or derivatives thereof using a dry powder drug delivery system. patentscope.wipo.int/search/en/detail.jsf?docId=US152764323patentscope.wipo.int/search/en/detail.jsf?docId=US152764323&tab=NATCOLLDOCUMENTS&maxRec=1000
|
|
|
Post by #NoMoreNeedles on Jan 2, 2019 13:56:15 GMT -5
What does Mike never mention them? Is this collaboration still active?
|
|